you're reading...
Autoimmune Diseases, Methotrexate, Ocular Inflammatory Diseases, Research

New Research Shows Promising Alternative to Methotrexate to Manage Inflammation

May 17, 2012 (Fort Lauderdale, Florida) — Mycophenolate mofetil (MMF) is superior to methotrexate for the treatment of ocular inflammatory diseases, according to a study presented here at the Association for Research in Vision and Ophthalmology 2012 Annual Meeting.

Using a marginal structural model to simulate a clinical trial comparing the 2 agents, the researchers, led by John H. Kempen, MD, PhD, director of the ocular inflammation service at the Scheie Eye Institute, University of Pennsylvania, in Philadelphia, found that “corticosteroid-sparing” (i.e., complete control of inflammation on prednisone 10 mg/day or less, sustained for at least 30 days) was achieved more rapidly with MMF than with methotrexate.

“While the method we used is not a perfect substitute for a randomized clinical trial, until such a trial can be done, these results provide a reasonably robust evidence base indicating that mycophenolate mofetil is superior to methotrexate in achieving corticosteroid-sparing goals,” Dr. Kempen told Medscape Medical News.

“It seems to work considerably faster, which is an important advantage, given the side effects that prolonged systemic corticosteroid therapy can have,” he said.

Read more.



No comments yet.

What do you think?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: